FibroBiologics, Inc. has 4 Schedule 13D or 13G filings on record since 2025-07-17. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.99% | 738,977 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Hamid Khoja | 7.5% | 630,009 | SCHEDULE 13D, 2026-09-17 | 2026-09-15 |
| Lind Global Fund III LP | 4.99% | 230,234 | SCHEDULE 13G, 2026-04-09 | 2026-04-02 |
| BlackRock, Inc. | 2% | 750,898 | SCHEDULE 13G/A, 2025-07-17 | 2025-06-30 |
Purpose of Transaction (Item 4)
Hamid Khoja
On September 15, 2026, the Issuer and the reporting person entered into a securities purchase agreement relating to the issuance and sale of 298,508 shares of the Issuer's common stock and accompanying warrants to purchase up to 298,508 shares of common stock in a private placement. The transaction closed on September 15, 2026. The warrants are exercisable at any time, have an exercise price of $1.55 per share, and expire on the five-year anniversary of the date of issuance. The warrants also contain standard anti-dilution adjustments to the exercise price including for stock splits, stock dividends, rights offerings and pro rata distributions. The Issuer issued the shares and warrants to the reporting person at an offering price of $1.675 per share and accompanying warrant for gross proceeds of approximately $0.5 million. The reporting person made the acquisition described above in support of the Issuer's business plan and for investment purposes. The reporting person may acquire or dispose of additional securities or sell securities of the Issuer from time to time in the market or in private transactions, including as a result of ownership of the warrants referred to above. However, the reporting person does not have any other agreements to acquire additional shares of common stock at this time, except for option agreements governing 102,965 outstanding options granted to the reporting person in the course of his employment with the Issuer. As Chief Scientific Officer of …The first part of Item 4 of the SCHEDULE 13D filed 2026-09-17; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 2% | SCHEDULE 13G/A |
| 2026-04-09 | Lind Global Fund III LP | 4.99% | SCHEDULE 13G |
| 2026-08-14 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G |
| 2026-09-17 | Hamid Khoja | 7.5% | SCHEDULE 13D |
FibroBiologics, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for FibroBiologics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.